AMINOSYN 8.5% INJECTION WITH ELECTROLYTES 102 MG / 100 ML — DIN 00613339
MAGNESIUM CHLORIDE : 102 MG / 100 ML SODIUM CHLORIDE : 410 MG / 100 ML TRYPTOPHAN : 150 MG / 100 ML HISTIDINE : 260 MG / 100 ML PROLINE : 750 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 522 MG / 100 ML ARGININE : 850 MG / 100 ML GLYCINE : 1.1 G / 100 ML TYROSINE : 44 MG / 100 ML LEUCINE : 810 MG / 100 ML LYSINE (LYSINE ACETATE) : 624 MG / 100 ML PHENYLALANINE : 380 MG / 100 ML VALINE : 680 MG / 100 ML L-ALANINE : 1.1 G / 100 ML SERINE : 370 MG / 100 ML ISOLEUCINE : 620 MG / 100 ML THREONINE : 460 MG / 100 ML METHIONINE : 340 MG / 100 ML · HOSPIRA HEALTHCARE ULC · SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is AMINOSYN 8.5% INJECTION WITH ELECTROLYTES?
AMINOSYN 8.5% INJECTION WITH ELECTROLYTES 102 MG / 100 ML contains MAGNESIUM CHLORIDE : 102 MG / 100 ML SODIUM CHLORIDE : 410 MG / 100 ML TRYPTOPHAN : 150 MG / 100 ML HISTIDINE : 260 MG / 100 ML PROLINE : 750 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 522 MG / 100 ML ARGININE : 850 MG / 100 ML GLYCINE : 1.1 G / 100 ML TYROSINE : 44 MG / 100 ML LEUCINE : 810 MG / 100 ML LYSINE (LYSINE ACETATE) : 624 MG / 100 ML PHENYLALANINE : 380 MG / 100 ML VALINE : 680 MG / 100 ML L-ALANINE : 1.1 G / 100 ML SERINE : 370 MG / 100 ML ISOLEUCINE : 620 MG / 100 ML THREONINE : 460 MG / 100 ML METHIONINE : 340 MG / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 00613339, held by HOSPIRA HEALTHCARE ULC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 03-Aug-2012. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is AMINOSYN 8.5% INJECTION WITH ELECTROLYTES used for?
Peripheral: nitrogen source for acute adult surgical patients (3-5 days). Central: adjunct in prevention of nitrogen loss or treatment of negative nitrogen balance when oral route is unusable.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Combinations cost around the world?
Combinations is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Czechia publishes a max producer price (ex-factory); Hungary publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Hungary | producer price (ex-factory) | 5 | 5 |
| Czechia | max producer price (ex-factory) | 1 | 1 |
| Iceland | max wholesale | 1 | 1 |
| Luxembourg | reimbursement | 1 | 1 |
8 pack listings across 8 brand entries and 4 price bases, refreshed 05 Sep 2026. Ranges span every Combinations pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
7 holders have a Canadian DIN containing Combinations, across 79 DINs, of which 22 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BAXTER CORPORATION | 34 | 17 | CLINIMIX, CLINIMIX E, OLIMEL 3.3% E, OLIMEL 4.4%, OLIMEL 4.4% E, +8 more | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 5 | 5 | SMOFKABIVEN, SMOFKABIVEN ELECTROLYTE FREE, SMOFKABIVEN EXTRA NITROGEN, SMOFKABIVEN EXTRA NITROGEN ELECTROLYTE FREE, SMOFKABIVEN PERIPHERAL | Sourceable in Canada |
| BAXTER CORPORATION CLINTEC NUTRITION DIVISION | 19 | 0 | 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE, 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE CLINIMIX, 2.5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 10% DEXTROSE QUICKMIX, 2.75% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 25% DEXTROSE QUICKMIX, 2.75% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 5% DEXTROSE QUICKMIX, +14 more | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 13 | 0 | AMINOSYN 8.5% INJECTION WITH ELECTROLYTES, AMINOSYN II 10% WITH ELECTROLYTES, AMINOSYN II 7% M IN 10% DEXTROSE(DUAL CHAMBER), AMINOSYN II 7% WITH 10% DEXTROSE, AMINOSYN II 7% WITH 50% DEXTROSE, +5 more | No marketed DIN |
| CLINTEC NUTRITION COMPANY | 5 | 0 | 2.5%TRAVASOL AMINO ACID INJ.W.ELEC.W.25%DEX, 2.75% TRAVAS. AMINO ACID INJ.W.ELECW.25%DEX, 2.75%TRAVASOL AMINO ACID INJ.W.ELEC.W.5%DEX., 4.25%TRAV. AMINO ACID INJ.W.O.ELECT.5%DEXT., 4.25%TRAVASOL AMINO ACID INJ.W.ELECW.5%DEX. | No marketed DIN |
| ABBOTT LABORATORIES, LIMITED | 2 | 0 | AMINOSYN 10% W ELECTROLYTES, AMINOSYN 3.5% M | No marketed DIN |
| FRESENIUS KABI AB | 1 | 0 | VAMIN N | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 102 MG / 100 ML |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 500 and 1000 mL PVC bags. |
| Storage | Store between 20° and 25°C. Do not freeze. Protect from light. Avoid excessive heat. Use promptly after mixing; refrigerated storage of mixtures max 24 hours. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Combinations |
|---|---|
| ATC code | B05BA10 |
| AHFS class | 56:12.00 ; 92:01.00* ; See footnote |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00613339 |
|---|---|
| DIN (unpadded, as printed on some documents) | 613339 |
| Brand name | AMINOSYN 8.5% INJECTION WITH ELECTROLYTES |
| Generic / active ingredient | MAGNESIUM CHLORIDE : 102 MG / 100 ML SODIUM CHLORIDE : 410 MG / 100 ML TRYPTOPHAN : 150 MG / 100 ML HISTIDINE : 260 MG / 100 ML PROLINE : 750 MG / 100 ML POTASSIUM PHOSPHATE DIBASIC : 522 MG / 100 ML ARGININE : 850 MG / 100 ML GLYCINE : 1.1 G / 100 ML TYROSINE : 44 MG / 100 ML LEUCINE : 810 MG / 100 ML LYSINE (LYSINE ACETATE) : 624 MG / 100 ML PHENYLALANINE : 380 MG / 100 ML VALINE : 680 MG / 100 ML L-ALANINE : 1.1 G / 100 ML SERINE : 370 MG / 100 ML ISOLEUCINE : 620 MG / 100 ML THREONINE : 460 MG / 100 ML METHIONINE : 340 MG / 100 ML |
| Market authorization holder | HOSPIRA HEALTHCARE ULC |
| Health Canada schedule | Ethical |
| ATC code | B05BA10 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B05BA |
| Current status | CANCELLED POST MARKET |
| Status date | 03-Aug-2012 |
| Original market date | 1985-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Total daily dose depends on protein requirements. Peripheral: dilute with sterile water, max 1.5 g/kg/day amino acids. Central: administer with concentrated dextrose for TPN.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to components; infants, children, or pregnant women; hepatic coma; anuria; metabolic disorders involving impaired nitrogen utilization; azotemia.
Warnings and precautions
May induce rise in BUN. Central venous administration requires expertise. Risk of hyperammonemia, metabolic alkalosis, and fluid/electrolyte overload in patients with organ insufficiency.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
22 of 79 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLINIMIX | 520 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02013940 |
| CLINIMIX | 310 MG / 100 ML | LIQUID | BAXTER CORPORATION | MARKETED | 02046709 |
| CLINIMIX | 10 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02498456 |
| CLINIMIX | 464 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02498464 |
| CLINIMIX | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02013932 |
| CLINIMIX | 230 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02013886 |
| CLINIMIX | 690 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02498448 |
| CLINIMIX E | 290 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02014076 |
| CLINIMIX E | 58.5 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02142384 |
| CLINIMIX E | 220 MG / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02013967 |
2 · Same class — other molecules in ATC B05BA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Combinations | 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE · 2.5% TRAVASOL AMINO ACID INJECTION WITH ELECTROLYTES IN 10% DEXTROSE CLINIMIX · 2.5% TRAVASOL AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 10% DEXTROSE QUICKMIX · 2.5%TRAVASOL AMINO ACID INJ.W.ELEC.W.25%DEX · +51 more | 79 | 22 | Yes |
| Carbohydrates | 10% DEXTROSE INJECTION USP · 10% DEXTROSE INJECTION, USP · 13.3% DEXTROSE INJECTION, USP · 20% DEXTROSE INJECTION USP · +18 more | 32 | 9 | Yes |
| Amino Acids | 20% PROSOL · 4.25% AMINO ACID INJECTION WITHOUT ELECTROLYTES IN 20% DEXTROSE QUICKMIX · 8.5% FREAMINE III · AMINOSYN · +20 more | 26 | 4 | Yes |
| Fat Emulsions | 10% TRAVAMULSION LIQ IV · 20% TRAVAMULSION LIQ IV · CLINOLEIC 20% · COLIP 20% · +9 more | 13 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B05B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B05BB | Electrolytes · Electrolytes With Carbohydrates | 90 | 27 |
| B05BC | Carbamide · Carbamide, Combinations · Mannitol | 11 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is AMINOSYN 8.5% INJECTION WITH ELECTROLYTES called?
The same molecule, Combinations, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ekyflogyl | Latin | Iceland |
| OTIPAX | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.